Inhibikase Q3 2026 net loss $20.5M; cash $193.3M to fund IMPROVE-PAH through Part B readout

Inhibikase Therapeutics, Inc.

Q3 2026 net loss $20.5M ($0.10/share) vs $11.9M ($0.13/share) a year earlier; R&D rose to $15.0M from $7.6M and SG&A to $7.2M from $5.6M.
Cash, cash equivalents and marketable securities were $193.3M at Sept 30, 2026, expected to fund operations through Part B topline, assuming full exercise of Series A and B warrants.
Phase 3 IMPROVE-PAH has 28 country regulatory approvals and 79 of a planned 180 sites activated; Part A interim safety readout (n=50) planned for first half of 2027.
July 2026: sold 25,000,000 shares to RA Capital via ATM for $50M gross; 18,030,000 later exchanged for pre-funded warrants. 140.3M shares and 60.6M pre-funded warrants outstanding.
FDA granted Orphan Drug Designation for IKT-001 in July 2026; board added cardiologist Scott M. Wasserman, MD, CMO of Kailera Therapeutics, in October 2026.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.